One might speculate that drug efflux may be suppressed by TGF-β1 inhibition because the expression of ATP-binding cassette transporters, such as ABCC10, emitting gefitinib from cells increased by TGF-β (Figures S14 and S15),43, 44, 45, 46 thereby suggesting retention and prolonged effect of gefitinib in NSCLC. The gene discussed is TGFB1; the disease is non-small cell lung carcinoma.